AAN 2021 | Impact of fcRn inhibitors on IgG-mediated autoimmune disorders

Myasthenia gravis, a chronic neuromuscular disorder, can be a very debilitating and potentially life-threatening disease leading to impairments that can adversely affect patients’ health-related quality of life. James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, outlines how the use of FcRn inhibitors such as efgartigimod can impact the treatment landscape of generalized myasthenia gravis. And ultimately replace the use of plasma exchange and intravenous immunoglobulin. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.